Psychedelic Substances May Decrease Criminal Behavior

July 20, 2021 14:20:32

A study conducted by researchers from the University of Alabama in collaboration with the University of British Columbia Okanagan Campus proposes that psychedelic substances such as mescaline, LSD and psilocybin mushrooms may decrease criminal offenses.

The study, which was co-authored by Zach Walsh, an associate professor in the Department of Psychology at UBC Okanagan, discovered that psychedelic substances were linked to a reduced likelihood of antisocial criminal behavior. Walsh stated that the team’s discovery adds to a growing body of research which suggests that the use of psychedelics may have a positive impact on decreasing antisocial behavior; he noted that this emphasized the need to conduct more research on the possibly beneficial effects of these currently illicit substances for public and individual health.

Peter Hendricks, an associate professor from the University of Alabama who was the lead author of the study, utilized data acquired by the National Survey on Drug Use and Health to investigate the connection between criminal behavior and the use of psychedelic drugs. The survey, which is administered by the Department of Health and Human Services, included more than 480,000 respondents who took the survey.

The research team discovered that respondents who used psychedelic substances had 22% less chance of being arrested for a violent crime and 27% less chances of committing theft or larceny. Concurrently, lifetime use of other illegal substances was generally linked to increased chances of engaging in criminal behavior.

The study was reported in the “Journal of Psychopharmacology.”

In the study, Hendricks stated that psilocybin and other compounds could revolutionize the field of mental health, adding that the development of effective and innovative interventions to hinder criminal behavior should be a priority. He also noted that the positive effects linked to the use of classic psychedelics such as LSD and psilocybin appeared to be reliable.

In addition to this, Walsh mentioned that research on the benefits of psychedelic substances began decades ago, mainly focused on the treatment of mental health conditions. However, he continued, the classification of substances such as LSD, cannabis, peyote and MDMA, together with heroin, under Schedule 1 of the Controlled Substances Act hindered the progression of the said research. Despite this classification, made in the 1970s, recent easing of the rules that govern these substances has sparked research on psychedelic medicine begin once more.

Walsh adds that the experiences of transcendence, positivity and unity that characterize the psychedelic experience may have long-term benefits that translate into actual consequences; Walsh did state that additional research is required to identify what factors underlie the effects of these substances.

While this research focused on the behavior modification potential of psychedelics is taking place, companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are putting their energies into finding how psychedelics can be used to treat chronic pain, eating disorders, fibromyalgia and a host of mental health challenges.

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.